Publicacións (36) Publicacións de Sergio Ruiz Llorente

filter_list

2025

  1. Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids

    Journal of Experimental and Clinical Cancer Research, Vol. 44, Núm. 1

  2. Promoción del conocimiento sobre el cáncer y su prevención en adolescentes mediante dinámicas de Aprendizaje-Servicio

    Formación crítica y reflexiva a través de la metodología Aprendizaje-Servicio: compromiso entre universidad y sociedad: XVI Encuentro de Innovación en Docencia Universitaria

  3. Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study

    Clinical and Translational Oncology, Vol. 27, Núm. 6, pp. 2719-2730

  4. Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 31, Núm. 9, pp. 1644-1656

2024

  1. Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer

    The Journal of clinical investigation, Vol. 134, Núm. 10

2023

  1. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

    Frontiers in Immunology, Vol. 14

2022

  1. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

    Virchows Archiv, Vol. 480, Núm. 4, pp. 855-871

  2. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 12, pp. 2432-2440

  3. Multivariate feature selection and autoencoder embeddings of ovarian cancer clinical and genetic data

    Expert Systems with Applications, Vol. 206

2021

  1. A Resampling Univariate Analysis Approach to Ovarian Cancer from Clinical and Genetic Data

    IEEE Access, Vol. 9, pp. 25959-25972

  2. Text Analytics and Mixed Feature Extraction in Ovarian Cancer Clinical and Genetic Data

    IEEE Access, Vol. 9, pp. 58034-58051

2019

  1. CREBBP/EP300 bromodomain inhibition affects the proliferation of AR-positive breast cancer cell lines

    Molecular Cancer Research, Vol. 17, Núm. 3, pp. 720-730

2018

  1. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation

    Epigenetics and Chromatin, Vol. 11, Núm. 1

2017

  1. Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Núm. 25, pp. E4951-E4960

2016

  1. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation

    Scientific Reports, Vol. 6

2013

  1. An Epistatic Interaction between the PAX8 and STK17B Genes in Papillary Thyroid Cancer Susceptibility

    PLoS ONE, Vol. 8, Núm. 9

  2. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF -mutant thyroid carcinomas

    Cancer Discovery, Vol. 3, Núm. 5, pp. 520-533

2012

  1. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line

    Nuclear Medicine and Biology, Vol. 39, Núm. 8, pp. 1275-1280

  2. Genome-wide analysis of Pax8 binding provides new insights into thyroid functions

    BMC Genomics, Vol. 13, Núm. 1

2009

  1. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors

    PLoS Genetics, Vol. 5, Núm. 9